Advances in Chimeric Antigen Receptor T-cell therapy for hematologic malignancies and autoimmune conditions: a review of the 2024 American Society of Hematology Annual Meeting

Frontiers in Hematology · Published 2025-06-23 · DOI 10.3389/frhem.2025.1610794

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.3389/frhem.2025.1610794

Abstract

Recent advancements in Chimeric Antigen Receptor T cell (CAR T) therapies and manufacturing technologies have expanded treatment options for patients with hematologic malignancies and autoimmune diseases. This review synthesizes the findings from abstracts and oral presentations delivered at the 66th American Society of Hematology (ASH) Annual Meeting. The clinical trial data featured in this review highlights the safety and efficacy of next-generation CAR T constructs, the efficiency of emerging manufacturing technologies, and the expanded indications for CAR T cell therapeutics.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year

2025

Related articles

• The role of necroptosis as a possible therapeutic target in multiple myeloma: the emerging roles of necroptosis · Frontiers in Hematology · 2026 · Same journal
• Case Report: A converging pathology: Chediak–Higashi syndrome and IEI-associated lymphoproliferative disease · Frontiers in Hematology · 2026 · Same journal
• Soluble immune checkpoint landscape in sickle cell disease links systemic inflammation, autoimmunity, and pain · Frontiers in Hematology · 2025 · Same journal
• Portuguese real-world experience with ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma · Frontiers in Hematology · 2025 · Same journal
• Real-world data of azacitidine for relapsed/refractory nodal T-follicular helper cell lymphoma in 11 patients · Frontiers in Hematology · 2025 · Same journal
• Case Report: two cases of idiopathic plasmacytic lymphadenopathy subtype of idiopathic multicentric Castleman disease with xanthelasma palpebrum from a Canadian center · Frontiers in Hematology · 2026 · Same journal
• Complications and treatment patterns in patients with non-transfusion-dependent α- and β-thalassemia compared with matched controls: a retrospective observational study using administrative claims data in the United States · Frontiers in Hematology · 2026 · Same journal
• Associations with the quality of life of adult family members or partners (informal carers) of people with leukaemia: results from a cross-sectional online global survey · Frontiers in Hematology · 2026 · Same journal
• Understanding therapy-related AML: genetic insights and emerging strategies for high-risk patients · Frontiers in Hematology · 2025 · Same journal
• The “added value” of enrolling hematological patients in clinical trials: a single-center experience · Frontiers in Hematology · 2025 · Same journal